SG Americas Securities’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-25,000
Closed -$34K – 3417
2024
Q2
$34K Buy
+25,000
New +$3.76M ﹤0.01% 2731
2022
Q4
– Sell
-150,000
Closed -$33K – 3062
2022
Q3
$33K Buy
+150,000
New +$19M ﹤0.01% 3050

Other funds holding AZN

SG Americas Securities's AZN Position: Q2 2026 in Review

SG Americas Securities reduced its AstraZeneca (AZN) stake by 41% in Q2 2026, selling an estimated $618K and leaving 4,728 shares worth $897K. The position accounts for ﹤0.01% of the portfolio, ranked #1952.

SG Americas Securities first reported a position in AZN in Q4 2016 and has held it in 35 quarters since. The position peaked at $23.3M in Q4 2025. 1,508 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • SG Americas Securities held 4,728 shares of AstraZeneca worth $897K as of Q2 2026.
  • SG Americas Securities sold 3,285 AstraZeneca shares in Q2 2026, an estimated $618K.
  • AstraZeneca made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1952 holding.
  • SG Americas Securities first reported a position in AstraZeneca in Q4 2016 and has held it in 35 quarters since.
  • SG Americas Securities's AstraZeneca position peaked at $23.3M in Q4 2025.
  • 1,508 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.